ADMA Biologics Earnings Estimate
| ADMA Stock | USD 16.43 0.49 3.07% |
ADMA Biologics Revenue Breakdown by Earning Segment
By analyzing ADMA Biologics' earnings estimates, investors can diagnose different trends across ADMA Biologics' analyst sentiment over time as well as compare current estimates against different timeframes. The current year's Gross Profit is expected to grow to about 265.1 M. The current year's Pretax Profit Margin is expected to grow to 0.28Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
ADMA Biologics Earnings Estimation Breakdown
The calculation of ADMA Biologics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of ADMA Biologics is estimated to be 0.2 with the future projection ranging from a low of 0.2 to a high of 0.2. Please be aware that this consensus of annual earnings estimates for ADMA Biologics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.20 Lowest | Expected EPS | 0.20 Highest |
ADMA Biologics Earnings Projection Consensus
Suppose the current estimates of ADMA Biologics' value are higher than the current market price of the ADMA Biologics stock. In this case, investors may conclude that ADMA Biologics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and ADMA Biologics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 3 | 55.53% | 0.0 | 0.2 | 0.86 |
ADMA Biologics Earnings per Share Projection vs Actual
Actual Earning per Share of ADMA Biologics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering ADMA Biologics predict the company's earnings will be in the future. The higher the earnings per share of ADMA Biologics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.ADMA Biologics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as ADMA Biologics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of ADMA Biologics should always be considered in relation to other companies to make a more educated investment decision.ADMA Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact ADMA Biologics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-11-05 | 2025-09-30 | 0.15 | 0.15 | 0.0 | 0 | ||
2025-08-06 | 2025-06-30 | 0.15 | 0.14 | -0.01 | 6 | ||
2025-05-07 | 2025-03-31 | 0.1467 | 0.11 | -0.0367 | 25 | ||
2025-02-26 | 2024-12-31 | 0.145 | 0.136 | -0.009 | 6 | ||
2024-11-07 | 2024-09-30 | 0.13 | 0.15 | 0.02 | 15 | ||
2024-08-08 | 2024-06-30 | 0.08 | 0.13 | 0.05 | 62 | ||
2024-05-09 | 2024-03-31 | 0.06 | 0.08 | 0.02 | 33 | ||
2024-02-28 | 2023-12-31 | 0.03 | -0.08 | -0.11 | 366 | ||
2023-11-08 | 2023-09-30 | -0.01 | 0.01 | 0.02 | 200 | ||
2023-08-09 | 2023-06-30 | -0.02 | -0.03 | -0.01 | 50 | ||
2023-05-10 | 2023-03-31 | -0.04 | -0.03 | 0.01 | 25 | ||
2023-03-23 | 2022-12-31 | -0.06 | -0.06 | 0.0 | 0 | ||
2022-11-09 | 2022-09-30 | -0.08 | -0.08 | 0.0 | 0 | ||
2022-08-10 | 2022-06-30 | -0.08 | -0.07 | 0.01 | 12 | ||
2022-05-11 | 2022-03-31 | -0.08 | -0.1 | -0.02 | 25 | ||
2022-03-24 | 2021-12-31 | -0.09 | -0.09 | 0.0 | 0 | ||
2021-11-10 | 2021-09-30 | -0.14 | -0.13 | 0.01 | 7 | ||
2021-08-11 | 2021-06-30 | -0.15 | -0.14 | 0.01 | 6 | ||
2021-05-12 | 2021-03-31 | -0.17 | -0.16 | 0.01 | 5 | ||
2021-03-25 | 2020-12-31 | -0.16 | -0.2 | -0.04 | 25 | ||
2020-11-05 | 2020-09-30 | -0.19 | -0.19 | 0.0 | 0 | ||
2020-08-05 | 2020-06-30 | -0.16 | -0.23 | -0.07 | 43 | ||
2020-05-06 | 2020-03-31 | -0.12 | -0.24 | -0.12 | 100 | ||
2020-03-12 | 2019-12-31 | -0.17 | -0.18 | -0.01 | 5 | ||
2019-11-06 | 2019-09-30 | -0.23 | -0.19 | 0.04 | 17 | ||
2019-08-08 | 2019-06-30 | -0.29 | -0.25 | 0.04 | 13 | ||
2019-05-08 | 2019-03-31 | -0.32 | -0.32 | 0.0 | 0 | ||
2019-03-13 | 2018-12-31 | -0.35 | -0.39 | -0.04 | 11 | ||
2018-11-08 | 2018-09-30 | -0.31 | -0.33 | -0.02 | 6 | ||
2018-08-10 | 2018-06-30 | -0.31 | -0.34 | -0.03 | 9 | ||
2018-05-14 | 2018-03-31 | -0.31 | -0.39 | -0.08 | 25 | ||
2018-03-05 | 2017-12-31 | -0.31 | -0.29 | 0.02 | 6 | ||
2017-11-03 | 2017-09-30 | -0.42 | -0.58 | -0.16 | 38 | ||
2017-08-11 | 2017-06-30 | -0.25 | -0.55 | -0.3 | 120 | ||
2017-05-12 | 2017-03-31 | -0.28 | -0.51 | -0.23 | 82 | ||
2017-02-24 | 2016-12-31 | -0.32 | -0.35 | -0.03 | 9 | ||
2016-11-10 | 2016-09-30 | -0.42 | -0.34 | 0.08 | 19 | ||
2016-08-12 | 2016-06-30 | -0.38 | -0.5 | -0.12 | 31 | ||
2016-05-13 | 2016-03-31 | -0.37 | -0.43 | -0.06 | 16 | ||
2016-03-23 | 2015-12-31 | -0.44 | -0.45 | -0.01 | 2 | ||
2015-11-10 | 2015-09-30 | -0.39 | -0.48 | -0.09 | 23 | ||
2015-08-11 | 2015-06-30 | -0.35 | -0.44 | -0.09 | 25 | ||
2015-05-12 | 2015-03-31 | -0.38 | -0.37 | 0.01 | 2 | ||
2015-03-09 | 2014-12-31 | -0.38 | -0.38 | 0.0 | 0 | ||
2014-11-10 | 2014-09-30 | -0.37 | -0.36 | 0.01 | 2 | ||
2014-08-11 | 2014-06-30 | -0.52 | -0.43 | 0.09 | 17 | ||
2014-05-12 | 2014-03-31 | -0.49 | -0.64 | -0.15 | 30 | ||
2014-03-28 | 2013-12-31 | -0.47 | -0.54 | -0.07 | 14 |
About ADMA Biologics Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of ADMA Biologics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current ADMA Biologics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as ADMA Biologics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -277.7 M | -291.6 M | |
| Retained Earnings Total Equity | -430.2 M | -408.7 M | |
| Earnings Yield | 0.04 | 0.05 | |
| Price Earnings Ratio | 18.20 | 19.11 | |
| Price Earnings To Growth Ratio | (0.02) | (0.03) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ADMA Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share 0.86 | Revenue Per Share | Quarterly Revenue Growth 0.12 | Return On Assets | Return On Equity |
ADMA Biologics's market price often diverges from its book value, the accounting figure shown on ADMA's balance sheet. Smart investors calculate ADMA Biologics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since ADMA Biologics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that ADMA Biologics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ADMA Biologics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.